• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Bangladeshi pharma draws comparison with Ranbaxy

      Posted AtNewKerala.com

      London: Bangladesh's biggest pharmaceutical company, Beximco, which will soon list in London's Alternative Investment Market, has drawn comparison with Indian pharmaceutical major Ranbaxy Laboratories.

      Beximco Pharmaceuticals - which makes anti-retrovirals to treat HIV - is the first Bangladeshi company to list in the capital. It is expected to have a market value of 60 million pounds ($105 million).

      Industry insiders are already touting it as the next Ranbaxy, the Indian company that took the generic pharmaceuticals industry by storm because of its ability to circumvent the global drug patent systems, The Telegraph reported.

      India has since lost its status as a developing nation under the global patent regime, meaning Ranbaxy can only produce drugs whose patents have expired.

      Salman Rahman, chairman of Beximco, told reporters that Bangladesh, however, was expected to enjoy the least developed country (LDC) status till 2016, which would mean his company could continue to make these drugs and export them to developing countries.

      This status also means the company will be ready to export drugs to the US and elsewhere when the patents expire. Beximco hopes that the US Food and Drug Administration would approve one of its factories by next year.

      Rahman added that the listing of Beximco, which has raised 12 million pounds by issuing global depositary receipts, was just the beginning for the conglomerate.

      The company is already listed on the Dhaka exchange, and its main owners - Rahman brothers - are among the richest Men in Bangladesh. The Beximco conglomerate consists of 28 separate companies.

      Rahman said Beximco wanted to list in London for "access to global investors" and that the listing would "improve the image of Bangladesh". He said the company wanted to raise more money a few months ago, but the markets were hit by the bombings in London and Bangladesh.

      "In spite of these blasts, our team was able to convince international investors to have confidence," he said.

      The company is believed to have held talks with the World Health Organisation about supplying its cheaper drugs to the organisation's programmes.

      The Telegraph reported that this would dismay Western pharmaceutical companies, which worry about developing countries taking advantage of their lack of patent enforcement to produce cheap drugs.

      Many international pharmaceutical businesses also work with Beximco, including Glaxo Smithkline, which subcontracts to it local production of the Asthma drug Ventolin.

      October 14, 2005


       

      Share this Article!

    Back to top^